233 research outputs found
Transmission of High-Power Electron Beams Through Small Apertures
Tests were performed to pass a 100 MeV, 430 kWatt c.w. electron beam from the
energy-recovery linac at the Jefferson Laboratory's FEL facility through a set
of small apertures in a 127 mm long aluminum block. Beam transmission losses of
3 p.p.m. through a 2 mm diameter aperture were maintained during a 7 hour
continuous run.Comment: arXiv admin note: text overlap with arXiv:1305.019
Measured Radiation and Background Levels During Transmission of Megawatt Electron Beams Through Millimeter Apertures
We report measurements of photon and neutron radiation levels observed while
transmitting a 0.43 MW electron beam through millimeter-sized apertures and
during beam-off, but accelerating gradient RF-on, operation. These measurements
were conducted at the Free-Electron Laser (FEL) facility of the Jefferson
National Accelerator Laboratory (JLab) using a 100 MeV electron beam from an
energy-recovery linear accelerator. The beam was directed successively through
6 mm, 4 mm, and 2 mm diameter apertures of length 127 mm in aluminum at a
maximum current of 4.3 mA (430 kW beam power). This study was conducted to
characterize radiation levels for experiments that need to operate in this
environment, such as the proposed DarkLight Experiment. We find that sustained
transmission of a 430 kW continuous-wave (CW) beam through a 2 mm aperture is
feasible with manageable beam-related backgrounds. We also find that during
beam-off, RF-on operation, multipactoring inside the niobium cavities of the
accelerator cryomodules is the primary source of ambient radiation when the
machine is tuned for 130 MeV operation.Comment: 9 pages, 11 figures, submitted to Nuclear Instruments and Methods in
Physics Research Section
Advances on ELIC Design Studies
An electron-ion collider of a center-of-mass energy up to 90 GeV at luminosity up to 1035 cm-2s-1 with both beams highly polarized is essential for exploring the new QCD frontier of strong color fields in nuclear and precisely imaging the sea-quarks and gluons in the nucleon. A conceptual design of a ring-ring collider based on CEBAF (ELIC) with energies up to 9 GeV for electrons/positrons and up to 225 GeV for protons and 100 GeV/u for ions has been proposed to fulfill the science desire and to serve as the next step for CEBAF after the planned 12 GeV energy upgrade of the fixed target program. Here, we summarize recent design progress for the ELIC complex with four interaction points (IP); including interaction region optics with chromatic aberration compensation scheme and complete lattices for the Figure-8 collider rings. Further optimization of crab crossing angles at the IPs, simulations of beam-beam interactions and electron polarization in the Figure-8 ring and its matching at the IPs are also discussed
ΠΠ΅ΠΏΠΎΡΡΠ΅Π΄ΡΡΠ²Π΅Π½Π½ΡΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π½ΠΎΠ²ΠΎΠ³ΠΎ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΠΊΠΎΠ³ΠΎ ΠΎΠΏΠΎΡΠ½ΠΎΠ³ΠΎ ΠΊΠΎΠ»ΡΡΠ° Π΄Π»Ρ ΠΊΠΎΡΡΠ΅ΠΊΡΠΈΠΈ ΠΌΠΈΡΡΠ°Π»ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ
Aim. To make the first clinical experience evaluation of the new biological closed support ring for mitral valve.Methods. 26 patients (16 men, 10 women, mean age 55 [49; 62] years) with dysplastic mitral insufficiency were implanted βNEORINGβ biological ring for the first time from March 2020 to June 2021. The etiological factor of the defect formation in all cases was the connective tissue dysplasia. The mean functional class of heart failure before surgery was 2 [2; 3] according to NYHA, the effective regurgitant orifice (ERO) was 0.4 [0.3; 0.5], vena contracta was 0.7 [0.6; 0.8]. Ten patients received rings of 28 mm diameter, ten patients β 30 mm, six patients β 32 mm.Results. No significant adverse events such as death from any causes, strokes, myocardial infarction, cardiac complications, bleeding, and return of regurgitation or failure of plastic surgery requiring reoperation, infective endocarditis after the intervention were observed. In two cases a permanent pacemaker was implanted due to sinus node dysfunction. At discharge all patients had no regurgitation (ERO 0), medium transvalvular gradient was 4.0 [3.0; 5.3] mm Hg. All the patients were assigned to NYHA functional class I heart failure after the surgery.Conclusion. New biological support ring βNEORINGβ (βNeoKorβ, Kemerovo) use in the middle age group of patients showed high hemodynamic efficiency, the absence of specific complications in the early stages after the surgery. It is planned to expand the clinical material on the use of the biological ring, as well as to evaluate the long-term results in the format of a prospective, randomized trial and compare the new device with the existing ones.Π¦Π΅Π»Ρ. ΠΡΠ΅Π½ΠΊΠ° ΠΏΠ΅ΡΠ²ΠΎΠ³ΠΎ ΠΎΠΏΡΡΠ° ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π½ΠΎΠ²ΠΎΠ³ΠΎ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π·Π°ΠΌΠΊΠ½ΡΡΠΎΠ³ΠΎ ΠΎΠΏΠΎΡΠ½ΠΎΠ³ΠΎ ΠΊΠΎΠ»ΡΡΠ° Π΄Π»Ρ ΠΌΠΈΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΠ»Π°ΠΏΠ°Π½Π° Β«ΠΠΠΠ ΠΠΠΒ» (ΠΠΠ Β«ΠΠ΅ΠΎΠΠΎΡΒ», ΠΠ΅ΠΌΠ΅ΡΠΎΠ²ΠΎ).ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π‘ ΠΌΠ°ΡΡΠ° 2020 Π³. ΠΏΠΎ ΠΈΡΠ½Ρ 2021 Π³. 26 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌ Ρ Π΄ΠΈΡΠΏΠ»Π°ΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΌΠΈΡΡΠ°Π»ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΡΡ Π²ΠΏΠ΅ΡΠ²ΡΠ΅ ΠΈΠΌΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π½ΠΎ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΊΠΎΠ»ΡΡΠΎ Β«ΠΠΠΠ ΠΠΠΒ» (16 ΠΌΡΠΆΡΠΈΠ½, 10 ΠΆΠ΅Π½ΡΠΈΠ½, ΡΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ 55 [49; 62] Π»Π΅Ρ). ΠΠΎ Π²ΡΠ΅Ρ
ΡΠ»ΡΡΠ°ΡΡ
ΡΡΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΠ°ΠΊΡΠΎΡΠΎΠΌ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΏΠΎΡΠΎΠΊΠ° ΡΠ²ΠΈΠ»Π°ΡΡ Π΄ΠΈΡΠΏΠ»Π°Π·ΠΈΡ ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ. Π‘ΡΠ΅Π΄Π½ΠΈΠΉ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠΉ ΠΊΠ»Π°ΡΡ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ Π΄ΠΎ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΈ ΡΠΎΡΡΠ°Π²ΠΈΠ» 2 [2; 3] ΠΏΠΎ ΠΊΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ NYHA, ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½Π°Ρ ΠΏΠ»ΠΎΡΠ°Π΄Ρ ΡΠ΅Π³ΡΡΠ³ΠΈΡΠ°ΡΠΈΠΈ (ERO) β 0,4 [0,3; 0,5] ΡΠΌ2 , vena contracta β 0,7 [0,6; 0,8] ΡΠΌ. ΠΠ΅ΡΡΡΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌ ΠΈΠΌΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π½Ρ ΠΊΠΎΠ»ΡΡΠ° Ρ Π΄ΠΈΠ°ΠΌΠ΅ΡΡΠΎΠΌ 28 ΠΌΠΌ, Π΄Π΅ΡΡΡΠΈ Π±ΠΎΠ»ΡΠ½ΡΠΌ β Ρ Π΄ΠΈΠ°ΠΌΠ΅ΡΡΠΎΠΌ 30 ΠΌΠΌ, ΡΠ΅ΡΡΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌ β Ρ Π΄ΠΈΠ°ΠΌΠ΅ΡΡΠΎΠΌ 32 ΠΌΠΌ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π’Π°ΠΊΠΈΡ
Π·Π½Π°ΡΠΈΠΌΡΡ
Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΡ
ΡΠΎΠ±ΡΡΠΈΠΉ, ΠΊΠ°ΠΊ ΡΠΌΠ΅ΡΡΡ ΠΎΡ Π²ΡΠ΅Ρ
ΠΏΡΠΈΡΠΈΠ½, ΠΈΠ½ΡΡΠ»ΡΡ, ΠΈΠ½ΡΠ°ΡΠΊΡ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π°, ΡΠ΅ΡΠ΄Π΅ΡΠ½ΡΠ΅ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΡ, ΠΊΡΠΎΠ²ΠΎΡΠ΅ΡΠ΅Π½ΠΈΡ, Π²ΠΎΠ·Π²ΡΠ°Ρ ΡΠ΅Π³ΡΡΠ³ΠΈΡΠ°ΡΠΈΠΈ ΠΈΠ»ΠΈ Π½Π΅ΡΠΎΡΡΠΎΡΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΠΏΠ»Π°ΡΡΠΈΠΊΠΈ, ΡΡΠ΅Π±ΡΡΡΠ°Ρ ΡΠ΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΈ, ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΎΠ½Π½ΡΠΉ ΡΠ½Π΄ΠΎΠΊΠ°ΡΠ΄ΠΈΡ ΠΏΠΎΡΠ»Π΅ Π²ΠΌΠ΅ΡΠ°ΡΠ΅Π»ΡΡΡΠ²Π°, Π½Π΅ ΠΎΡΠΌΠ΅ΡΠ΅Π½ΠΎ Π½ΠΈ Π² ΠΎΠ΄Π½ΠΎΠΌ ΡΠ»ΡΡΠ°Π΅. ΠΠ²ΡΠΌ Π±ΠΎΠ»ΡΠ½ΡΠΌ ΠΈΠΌΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π½ ΠΏΠΎΡΡΠΎΡΠ½Π½ΡΠΉ Π²ΠΎΠ΄ΠΈΡΠ΅Π»Ρ ΡΠΈΡΠΌΠ° ΠΏΠΎ ΠΏΡΠΈΡΠΈΠ½Π΅ Π΄ΠΈΡΡΡΠ½ΠΊΡΠΈΠΈ ΡΠΈΠ½ΡΡΠΎΠ²ΠΎΠ³ΠΎ ΡΠ·Π»Π°. ΠΠ° ΠΌΠΎΠΌΠ΅Π½Ρ Π²ΡΠΏΠΈΡΠΊΠΈ Ρ Π²ΡΠ΅Ρ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΎΡΡΡΡΡΡΠ²ΠΎΠ²Π°Π»Π° ΡΠ΅Π³ΡΡΠ³ΠΈΡΠ°ΡΠΈΡ (ERO 0), ΡΡΠ΅Π΄Π½ΠΈΠΉ ΡΡΠ°Π½ΡΠΊΠ»Π°ΠΏΠ°Π½Π½ΡΠΉ Π³ΡΠ°Π΄ΠΈΠ΅Π½Ρ ΡΠΎΡΡΠ°Π²ΠΈΠ» 4,0 [3,0; 5,3] ΠΌΠΌ ΡΡ. ΡΡ. ΠΠΎΡΠ»Π΅ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΈ Π²ΡΠ΅ Π±ΠΎΠ»ΡΠ½ΡΠ΅ Π±ΡΠ»ΠΈ ΠΎΡΠ½Π΅ΡΠ΅Π½Ρ ΠΊ I ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠΌΡ ΠΊΠ»Π°ΡΡΡ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ ΠΏΠΎ NYHA.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ Π½ΠΎΠ²ΠΎΠ³ΠΎ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΎΠΏΠΎΡΠ½ΠΎΠ³ΠΎ ΠΊΠΎΠ»ΡΡΠ° Β«ΠΠΠΠ ΠΠΠΒ» Π² ΡΡΠ΅Π΄Π½Π΅ΠΉ Π²ΠΎΠ·ΡΠ°ΡΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΎ Π²ΡΡΠΎΠΊΡΡ Π³Π΅ΠΌΠΎΠ΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΈ ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ Π² ΡΠ°Π½Π½ΠΈΠ΅ ΡΡΠΎΠΊΠΈ ΠΏΠΎΡΠ»Π΅ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΈ. ΠΠ»Π°Π½ΠΈΡΡΠ΅ΡΡΡ ΡΠ°ΡΡΠΈΡΠΈΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΊΠΎΠ»ΡΡΠ°, ΠΏΡΠΎΠ²Π΅ΡΡΠΈ ΠΎΡΠ΅Π½ΠΊΡ ΠΎΡΠ΄Π°Π»Π΅Π½Π½ΡΡ
ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² Π² ΡΠΎΡΠΌΠ°ΡΠ΅ ΠΏΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΡΠ°Π½Π΄ΠΎΠΌΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ, Π° ΡΠ°ΠΊΠΆΠ΅ ΡΡΠ°Π²Π½Π΅Π½ΠΈΠ΅ Π½ΠΎΠ²ΠΎΠ³ΠΎ ΠΈΠ·Π΄Π΅Π»ΠΈΡ Ρ ΡΠΆΠ΅ ΡΡΡΠ΅ΡΡΠ²ΡΡΡΠΈΠΌΠΈ ΠΌΠΎΠ΄Π΅Π»ΡΠΌΠΈ
Analysis of pneumococcal serotypes distribution to determine a model composition for a Russian pneumococcal conjugate vaccine
Diseases caused by Streptococcus pneumoniae, as well as antibiotic resistance of its serotypes, are the leading cause of death amongst children worldwide. To prevent pneumococcal infection, the population is immunised with conjugate vaccines containing different amounts of polysaccharides of certain serotypes. Development of a full-cycle Russian vaccine is vital because the active pharmaceutical ingredients for the vaccines registered in the Russian Federation are produced abroad, and only the final stages of production of vaccines of this group are performed in the territory of the Russian Federation. Considering the phenomenon of serotype replacement associated with the long-term widespread use of pneumococcal conjugate vaccines, it is necessary to carefully select the serotype composition for the new vaccine. The aim of this work was to analyse the serotype distribution of pneumococci in the Russian Federation and other countries in order to select optimal serotypes for the Russian vaccine for human use, taking into account vaccination schedules for each age group. This review presents an analysis of the pneumococcal serotype distribution in the Russian Federation in the pre-vaccination era, as well as after the introduction of routine vaccination. In addition, the review includes data on the serotype distribution in the Eurasian Economic Union countries. The authors described a model composition containing at least sixteen serotypes. It will increase effectiveness of immune protection of the population, providing a more complete coverage of serotypes, considering their prevalence in the Russian Federation. Based on the analysis, the serotype composition for the sixteen-valent pneumococcal conjugate vaccine is proposed for further production and preclinical and clinical trials. A new Russian pneumococcal conjugate vaccine will ensure vaccination of all population groups within the National Immunisation Schedule of the Russian Federation
Π‘ΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΡΡΠ΅Π΄Π½Π΅ΡΡΠΎΡΠ½ΡΡ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² ΠΊΠΎΡΡΠ΅ΠΊΡΠΈΠΈ ΠΌΠΈΡΡΠ°Π»ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ Ρ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ΠΌ ΠΎΠΏΠΎΡΠ½ΡΡ ΠΊΠΎΠ»Π΅Ρ NeoRing ΠΈ RIGID: ΠΏΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ΅ ΡΠ°Π½Π΄ΠΎΠΌΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅
Highlights. For the first time, as part of a prospective randomized study, a comparative assessment of the mid-term results of mitral valve annuloplasty using a new biological NeoRing ring (CJSC NeoKor, Kemerovo) and a RIGID ring (CJSC NPP MedInzh, Penza) in patients with connective tissue dysplasia was carried out. Predictors of the conversion of sinus rhythm to atrial fibrillation and residual mitral insufficiency in the medium-term follow-up period were determined.Aim. To analysis and compare mid-term results of mitral valve annuloplasty conducted using NeoRing ΠΈ RIGID rings.Methods. From November 2019 to March 2022, 62 patients with mitral valve (MV) dysplasia underwent MV annuloplasty using NeoRing semi-rigid rings (CJSC NeoKor, Kemerovo, n = 31) and rigid RIGID rings (CJSC NPP MedInzh, Penza, n = 31). There were no differences between the groups at baseline.Results. Two deaths were registered during inpatient treatment in the RIGID group. Both devices showed a satisfactory outcome during inpatient treatment in the form of restoration of MV function (p<0.001) and the frequency of detected maximum residual mitral regurgitation (MR) up to grade 1 in the NeoRing group 9.7% and in the RIGID group 29%, respectively, no statistically significant intergroup differences were noted (p = 0.292). After 12 months, freedom from β₯2 grade MR in the NeoRing group was 93.5% and 77.4% in the RIGID group (p = 0.147). In the RIGID group, patients had higher values of the transvalvular mitral diastolic gradient β PAV 3.70 [3.00β4.40] mm Hg vs. NeoRing group 2.3 [2.05β2.85] mmHg (p<0.001), as well as a higher transvalvular flow rate β VAV 79 [71β94] cm/sec vs. 70 [64β79] cm/sec (p = 0.017). The analysis of the achievement of composite primary endpoint (recurrence of β₯2 grade MR, MACCE, new onset arrhythmias, reoperations) by the device was carried out. The composite endpoint rate in the RIGID group was 3.067 times higher compared to the NeoRing group, odds differences were statistically significant (p = 0.037, 95% CI: 1.053β8.934).Conclusion. The outcome of MV annuloplasty conducted using rigid and semi-rigid rings revealed no significant differences in long-term survival and recurrence of MR between groups. Given the statistically significant difference in achieving the combined endpoint, lower inpatient and long-term indicators of transmitral pressure gradient, and a positive effect on cardiac chambers reverse remodeling, it was concluded that the use of semi-rigid NeoRing rings for MV annuloplasty when performing valvepreserving operations for connective tissue dysplasia is preferable.ΠΡΠ½ΠΎΠ²Π½ΡΠ΅ ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΡ. ΠΠΏΠ΅ΡΠ²ΡΠ΅ Π² ΡΠ°ΠΌΠΊΠ°Ρ
ΠΏΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΡΠ°Π½Π΄ΠΎΠΌΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π° ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½Π°Ρ ΠΎΡΠ΅Π½ΠΊΠ° ΡΡΠ΅Π΄Π½Π΅ΡΡΠΎΡΠ½ΡΡ
ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π½ΠΎΠ²ΠΎΠ³ΠΎ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΊΠΎΠ»ΡΡΠ° NeoRing (ΠΠΠ Β«ΠΠ΅ΠΎΠΠΎΡΒ», ΠΠ΅ΠΌΠ΅ΡΠΎΠ²ΠΎ) ΠΈ ΠΊΠΎΠ»ΡΡΠ° RIGID (ΠΠΠ ΠΠΠ Β«ΠΠ΅Π΄ΠΠ½ΠΆΒ», ΠΠ΅Π½Π·Π°) Π΄Π»Ρ Π°Π½Π½ΡΠ»ΠΎΠΏΠ»Π°ΡΡΠΈΠΊΠΈ ΠΌΠΈΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΠ»Π°ΠΏΠ°Π½Π° ΠΏΡΠΈ Π΄ΠΈΡΠΏΠ»Π°Π·ΠΈΠΈ ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ. ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Ρ ΠΏΡΠ΅Π΄ΠΈΠΊΡΠΎΡΡ ΡΠΌΠ΅Π½Ρ ΡΠΈΠ½ΡΡΠΎΠ²ΠΎΠ³ΠΎ ΡΠΈΡΠΌΠ° Π½Π° ΡΠΈΠ±ΡΠΈΠ»Π»ΡΡΠΈΡ ΠΏΡΠ΅Π΄ΡΠ΅ΡΠ΄ΠΈΠΉ ΠΈ Π²ΠΎΠ·Π²ΡΠ°ΡΠ° Π·Π½Π°ΡΠΈΠΌΠΎΠΉ ΠΌΠΈΡΡΠ°Π»ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ Π² ΡΡΠ΅Π΄Π½Π΅ΡΡΠΎΡΠ½ΠΎΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ.Π¦Π΅Π»Ρ. Π‘ΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΡΡΠ΅Π΄Π½Π΅ΡΡΠΎΡΠ½ΡΡ
ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΎΠΏΠΎΡΠ½ΡΡ
ΠΊΠΎΠ»Π΅Ρ NeoRing ΠΈ RIGID Π² Ρ
ΠΈΡΡΡΠ³ΠΈΠΈ ΠΌΠΈΡΡΠ°Π»ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ (ΠΠ).ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π‘ Π½ΠΎΡΠ±ΡΡ 2019 Π³. ΠΏΠΎ ΠΌΠ°ΡΡ 2022 Π³. 62 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌ Ρ Π΄ΠΈΡΠΏΠ»Π°ΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΠ Π²ΡΠΏΠΎΠ»Π½Π΅Π½Π° ΡΠ΅ΠΊΠΎΠ½ΡΡΡΡΠΊΡΠΈΡ ΠΌΠΈΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΠ»Π°ΠΏΠ°Π½Π° (ΠΠ) Ρ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ΠΌ ΠΏΠΎΠ»ΡΠΆΠ΅ΡΡΠΊΠΈΡ
ΠΊΠΎΠ»Π΅Ρ NeoRing (ΠΠΠ Β«ΠΠ΅ΠΎΠΠΎΡΒ», ΠΠ΅ΠΌΠ΅ΡΠΎΠ²ΠΎ; n = 31) ΠΈ ΠΆΠ΅ΡΡΠΊΠΈΡ
ΠΊΠΎΠ»Π΅Ρ RIGID (ΠΠΠ ΠΠΠ Β«ΠΠ΅Π΄ΠΠ½ΠΆΒ», ΠΠ΅Π½Π·Π°; n = 31). ΠΠΎ ΠΈΡΡ
ΠΎΠ΄Π½ΡΠΌ Π΄Π°Π½Π½ΡΠΌ ΡΠ°Π·Π»ΠΈΡΠΈΠΉ ΠΌΠ΅ΠΆΠ΄Ρ Π³ΡΡΠΏΠΏΠ°ΠΌΠΈ Π½Π΅ Π²ΡΡΠ²Π»Π΅Π½ΠΎ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠ°ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π½ΠΎ Π΄Π²Π° Π»Π΅ΡΠ°Π»ΡΠ½ΡΡ
ΡΠ»ΡΡΠ°Ρ Π² Π³ΠΎΡΠΏΠΈΡΠ°Π»ΡΠ½ΠΎΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅ Π² Π³ΡΡΠΏΠΏΠ΅ RIGID. ΠΠ±Π° ΡΡΡΡΠΎΠΉΡΡΠ²Π° ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΈ ΡΠ΄ΠΎΠ²Π»Π΅ΡΠ²ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΡΡΠ΅ΠΊΡ Π½Π° Π³ΠΎΡΠΏΠΈΡΠ°Π»ΡΠ½ΠΎΠΌ ΡΡΠ°ΠΏΠ΅ Π² Π²ΠΈΠ΄Π΅ Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ Π·Π°ΠΏΠΈΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΡΠ½ΠΊΡΠΈΠΈ ΠΠ (p<0,001) ΠΈ ΡΠ°ΡΡΠΎΡΠ΅ Π²ΡΡΠ²Π»Π΅Π½Π½ΠΎΠΉ ΠΌΠ°ΠΊΡΠΈΠΌΠ°Π»ΡΠ½ΠΎΠΉ ΡΠ΅Π·ΠΈΠ΄ΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΠ Π΄ΠΎ 1-ΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ Π² Π³ΡΡΠΏΠΏΠ°Ρ
NeoRing (9,7%) ΠΈ RIGID (29%) ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ, ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΡΡ
ΠΌΠ΅ΠΆΠ³ΡΡΠΏΠΏΠΎΠ²ΡΡ
ΡΠ°Π·Π»ΠΈΡΠΈΠΉ Π½Π΅ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½ΠΎ (p = 0,292). Π§Π΅ΡΠ΅Π· 12 ΠΌΠ΅Ρ. ΡΠ²ΠΎΠ±ΠΎΠ΄Π° ΠΎΡ ΠΠ β₯2 ΡΡΠ΅ΠΏΠ΅Π½ΠΈ Π² Π³ΡΡΠΏΠΏΠ΅ NeoRing ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 93,5%, Π² Π³ΡΡΠΏΠΏΠ΅ RIGID β 77,4% (p = 0,147). Π£ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ RIGID ΠΎΡΠΌΠ΅ΡΠ΅Π½Ρ Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΡΡΠ°Π½ΡΠΊΠ»Π°ΠΏΠ°Π½Π½ΠΎΠ³ΠΎ Π΄ΠΈΠ°ΡΡΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π³ΡΠ°Π΄ΠΈΠ΅Π½ΡΠ° Π½Π° ΠΠ β PΡΡ. 3,70 [3,00β4,40] ΠΏΡΠΎΡΠΈΠ² 2,3 [2,05β2,85] ΠΌΠΌ ΡΡ. ΡΡ. Π΄Π»Ρ NeoRing (p<0,001), Π° ΡΠ°ΠΊΠΆΠ΅ Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΠ°Ρ ΡΠΊΠΎΡΠΎΡΡΡ ΡΡΠ°Π½ΡΠΊΠ»Π°ΠΏΠ°Π½Π½ΠΎΠ³ΠΎ ΠΏΠΎΡΠΎΠΊΠ° β VΡΡ. 79 [71β94] ΠΏΡΠΎΡΠΈΠ² 70 [64β79] ΡΠΌ/Ρ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ (p = 0,017). ΠΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½ΠΎ Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΠ΅ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠΉ ΠΊΠΎΠ½Π΅ΡΠ½ΠΎΠΉ ΡΠΎΡΠΊΠΈ Π² Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ ΠΈΠΌΠΏΠ»Π°Π½ΡΠΈΡΡΠ΅ΠΌΠΎΠ³ΠΎ ΡΡΡΡΠΎΠΉΡΡΠ²Π°, ΡΠ°Π½ΡΡ Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΡ ΠΏΠΎ ΡΡΠΌΠΌΠΈΡΡΠ΅ΠΌΡΠΌ ΠΊΡΠΈΡΠ΅ΡΠΈΡΠΌ (ΡΠ΅ΡΠΈΠ΄ΠΈΠ² ΠΌΠΈΡΡΠ°Π»ΡΠ½ΠΎΠΉ ΡΠ΅Π³ΡΡΠ³ΠΈΡΠ°ΡΠΈΠΈ β₯2 ΡΡΠ΅ΠΏΠ΅Π½ΠΈ, MACCE, Π²ΠΏΠ΅ΡΠ²ΡΠ΅ Π·Π°ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ Π½Π°ΡΡΡΠ΅Π½ΠΈΡ ΡΠΈΡΠΌΠ°, ΡΠ΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΈ) Π² Π³ΡΡΠΏΠΏΠ΅ RIGID Π±ΡΠ»ΠΈ Π² 3,067 ΡΠ°Π·Π° Π²ΡΡΠ΅, ΡΠ΅ΠΌ Π² Π³ΡΡΠΏΠΏΠ΅ NeoRing; ΡΠ°Π·Π»ΠΈΡΠΈΡ ΡΠ°Π½ΡΠΎΠ² ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΡΠ΅ (95% ΠΠ 1,053β8,934; p = 0,037).ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΡΠΈ Π°Π½Π½ΡΠ»ΠΎΠΏΠ»Π°ΡΡΠΈΠΊΠ΅ ΡΠΈΠ±ΡΠΎΠ·Π½ΠΎΠ³ΠΎ ΠΊΠΎΠ»ΡΡΠ° ΠΠ ΠΆΠ΅ΡΡΠΊΠΈΠΌΠΈ ΠΈ ΠΏΠΎΠ»ΡΠΆΠ΅ΡΡΠΊΠΈΠΌΠΈ ΠΎΠΏΠΎΡΠ½ΡΠΌΠΈ ΠΊΠΎΠ»ΡΡΠ°ΠΌΠΈ Π½Π΅ ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π½ΠΎ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΡΠ°Π·Π½ΠΈΡΡ ΠΎΡΠ΄Π°Π»Π΅Π½Π½ΠΎΠΉ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ ΠΈ ΡΠ΅ΡΠΈΠ΄ΠΈΠ²ΠΎΠ² ΠΠ. Π‘ ΡΡΠ΅ΡΠΎΠΌ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΡΡ
ΡΠ°Π·Π»ΠΈΡΠΈΠΉ Π² Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΊΠΎΠ½Π΅ΡΠ½ΠΎΠΉ ΡΠΎΡΠΊΠΈ, Π±ΠΎΠ»Π΅Π΅ Π½ΠΈΠ·ΠΊΠΈΡ
Π³ΠΎΡΠΏΠΈΡΠ°Π»ΡΠ½ΡΡ
ΠΈ ΠΎΡΠ΄Π°Π»Π΅Π½Π½ΡΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΡΡΠ°Π½ΡΠΌΠΈΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π΄ΠΈΠ°ΡΡΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π³ΡΠ°Π΄ΠΈΠ΅Π½ΡΠ°, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ Π²Π»ΠΈΡΠ½ΠΈΡ Π½Π° ΠΎΠ±ΡΠ°ΡΠ½ΠΎΠ΅ ΡΠ΅ΠΌΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΊΠ°ΠΌΠ΅Ρ ΡΠ΅ΡΠ΄ΡΠ° ΡΠ΄Π΅Π»Π°Π½ Π²ΡΠ²ΠΎΠ΄, ΡΡΠΎ ΠΊΠ»Π°ΠΏΠ°Π½ΠΎΡΠΎΡ
ΡΠ°Π½ΡΡΡΠ°Ρ ΠΏΠ»Π°ΡΡΠΈΠΊΠ° ΠΠ ΠΏΠΎΠ»ΡΠΆΠ΅ΡΡΠΊΠΈΠΌΠΈ ΠΊΠΎΠ»ΡΡΠ°ΠΌΠΈ ΡΠΈΠΏΠ° NeoRing ΠΏΡΠΈ Π΄ΠΈΡΠΏΠ»Π°Π·ΠΈΠΈ ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΏΡΠ΅Π΄ΠΏΠΎΡΡΠΈΡΠ΅Π»ΡΠ½ΡΠΌ Π²Π°ΡΠΈΠ°Π½ΡΠΎΠΌ
- β¦